Trial intelligence / Profile preview

Remdesivir to Prevent Severe COVID-19 in Kidney Transplant Recipients

NCT07197164Phase 2

Key facts

Status: Recruiting
Start: Sep 2025
Primary completion: Dec 2026
Countries: 1
Modality: Orthosteric Ligands, Metabolically Activated Prodrugs

Drugs: remdesivir
Conditions: coronavirus disease 2019 (COVID-19)

Overview

Phase 2, open-label, single-arm trial of remdesivir in coronavirus disease 2019 (COVID-19). Primary endpoint: Number and proportion of participants who develop severe COVID-19 following kidney transplantation at 90 days. Started Sep 2025; status: recruiting.

Design

1 arm

Study design: Non-randomizedOpen-labelSingle group

Single Arm
Participants receive Remdesivir for 10 days starting 24h before transplant.

Who it enrols

Adult patients with end-stage kidney disease on the transplant waiting list who have a positive SARS-CoV-2 test within 5 days prior to transplant, are asymptomatic or mild, and have received at least 3 vaccine doses.

Endpoints

Primary

Number and proportion of participants who develop severe COVID-19 following kidney transplantation90 days

Secondary

Number of deaths (all causes mortality)90 days
Time to resolution and to recovery of all targeted symptoms90 days
Proportion of participants requiring extension of the hospitalization beyond POD1028 days
Proportion of participants with symptomatic rebound28 days
Clearance kinetics of SARS-CoV-2 infectionDay 28
Number of Participants with Treatment-Related Adverse Events6 months
Incidence of graft complicationsDay 90

Beyond the preview

Go deeper on NCT07197164.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07197164.